Stock Events

Stock Events

SynAct Pharma AB. 

€1.62
0
-€0.01-0.74% Wednesday 06:05

Statistics

Day High
1.62
Day Low
1.62
52W High
1.88
52W Low
1.57
Volume
0
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27MayExpected
Q4 2025
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8F8.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
State Street SPDR S&P Biotech
XBI
Mkt Cap0
SPDR S&P Biotech ETF, includes diverse biotech firms, some of which compete in similar therapeutic areas as SynAct Pharma.
iShares Biotechnology
IBB
Mkt Cap0
iShares Biotechnology ETF, holds biotech companies that may have overlapping development programs with SynAct Pharma.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals, involved in creating therapies for inflammatory diseases, a field SynAct Pharma is also targeting.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals, develops treatments for inflammatory conditions, directly competing with SynAct Pharma's pipeline.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, focuses on inflammatory and other diseases, competing in the same therapeutic areas as SynAct Pharma.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie, has a strong portfolio in immunology and inflammatory diseases, areas SynAct Pharma is also exploring.
AMGEN
AMGN
Mkt Cap189.22B
Amgen, a leader in biotechnology with drugs for inflammatory diseases, which overlaps with SynAct Pharma's focus.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol-Myers Squibb, offers products in the inflammation and immunology segment, competing with SynAct Pharma.
Novartis
NVS
Mkt Cap297.35B
Novartis, has extensive research and products in the area of inflammatory diseases, similar to SynAct Pharma's interests.
Pfizer
PFE
Mkt Cap153.13B
Pfizer, develops and markets drugs for inflammatory diseases, directly competing with SynAct Pharma's research and products.

About

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
Show more...
CEO
Mr. Jeppe Ovli Ovlesen EE, MBA
Employees
8
Country
Sweden
ISIN
SE0008241491

Listings

F
DE
8F8.F
STU
DE
8F8.STU
MU
DE
8F8.MU
ST
SE
SYNACT.ST

0 Comments

Share your thoughts

FAQ

What is SynAct Pharma AB. stock price today?▼
The current price of 8F8.MU is €1.62 EUR — it has decreased by -0.74% in the past 24 hours. Watch SynAct Pharma AB. stock price performance more closely on the chart.
What is SynAct Pharma AB. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange SynAct Pharma AB. stocks are traded under the ticker 8F8.MU.
When is the next SynAct Pharma AB. earnings date?▼
SynAct Pharma AB. is going to release the next earnings report on May 27, 2026.
How many employees does SynAct Pharma AB. have?▼
As of April 16, 2026, the company has 8 employees.
In which sector is SynAct Pharma AB. located?▼
SynAct Pharma AB. operates in the Health & Wellness sector.
When did SynAct Pharma AB. complete a stock split?▼
SynAct Pharma AB. has not had any recent stock splits.
Where is SynAct Pharma AB. headquartered?▼
SynAct Pharma AB. is headquartered in Lund, Sweden.